 Graphite Bio Inc. received a warm reception on Wall Street, as the California-based gene-editing biotechnology companys stock opened 30 above its initial public offering price. The IPO priced overnight at 17 a share, at the top of the expected range of between 15 and 17 a share, as the company raised 238 million. 